Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 191pembrolizumab 155Pemetrexed 134Cisplatin 117durvalumab 71Paclitaxel 71osimertinib 67Nivolumab 66Docetaxel 63Specimen Handling 61atezolizumab 57Magnetic Resonance Spectroscopy 50Etoposide 46Gemcitabine 42Radiotherapy 39Radiosurgery 37130-nm albumin-bound paclitaxel 34Drug Therapy 30Cetuximab 28Bevacizumab 27Ipilimumab 25Taxes 23cemiplimab 22tislelizumab 20Platinum 20amivantamab 18Radiation 18Immunoglobulin G 171,2-diaminocyclohexaneplatinum II citrate 17Disulfides 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
taletrectinib × Thoracic × 90 days × Clear all
NCT07154706 2026-05-19

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Nuvation Bio Inc.

Phase 3 Recruiting
180 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06564324 2026-04-13

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Nuvation Bio Inc.

Phase 3 Recruiting
194 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡